Last reviewed · How we verify
Ga-68-PSMA-11
Ga-68-PSMA-11 is a Small molecule drug developed by Timothy Hoffman. It is currently FDA-approved. Also known as: 68Ga-DKFZ-PSMA, 68Ga-PSMA, 68Ga-PSMA(HBED), Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)].
At a glance
| Generic name | Ga-68-PSMA-11 |
|---|---|
| Also known as | 68Ga-DKFZ-PSMA, 68Ga-PSMA, 68Ga-PSMA(HBED), Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)] |
| Sponsor | Timothy Hoffman |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PHASE3)
- Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan (PHASE2)
- Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial (PHASE2)
- 68Ga-PSMA PET in the Renal Cell Carcinoma (NA)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (PHASE3)
- Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) (PHASE2)
- COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ga-68-PSMA-11 CI brief — competitive landscape report
- Ga-68-PSMA-11 updates RSS · CI watch RSS
- Timothy Hoffman portfolio CI
Frequently asked questions about Ga-68-PSMA-11
What is Ga-68-PSMA-11?
Ga-68-PSMA-11 is a Small molecule drug developed by Timothy Hoffman.
Who makes Ga-68-PSMA-11?
Ga-68-PSMA-11 is developed and marketed by Timothy Hoffman (see full Timothy Hoffman pipeline at /company/timothy-hoffman).
Is Ga-68-PSMA-11 also known as anything else?
Ga-68-PSMA-11 is also known as 68Ga-DKFZ-PSMA, 68Ga-PSMA, 68Ga-PSMA(HBED), Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)].
What development phase is Ga-68-PSMA-11 in?
Ga-68-PSMA-11 is FDA-approved (marketed).
Related
- Manufacturer: Timothy Hoffman — full pipeline
- Also known as: 68Ga-DKFZ-PSMA, 68Ga-PSMA, 68Ga-PSMA(HBED), Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)]
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing